Talquetamab Infection Burden: Half Any-Grade, One-Fifth Severe

This meta-analysis quantifies the infection risk pharmacists must anticipate and prophylax against when dispensing talquetamab for heavily pretreated myeloma.

talquetamabGPRC5D bispecific antibodyteclistamabdaratumumabrelapsed refractory multiple myelomainfection riskmeta-analysissystematic reviewPJP prophylaxisIVIGoncology pharmacy Oncology Pharmacy

Background Information

Talquetamab raises infection concerns in RRMM patients.

Understanding infection risk associated with talquetamab assists in better managing relapsed/refractory multiple myeloma (RRMM) therapeutics. Talquetamab monotherapy showed a 51% incidence of any-grade infections and 22% for grade ≥3 infections, with infection-related mortality up to 3.2%. Infection risks vary by regimen and patient factors, suggesting a need for enhanced surveillance and prevention in RRMM treatments using talquetamab. Talquetamab therapy in RRMM poses significant infection risks, warranting careful monitoring and preventive strategies.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Huang ZY, Wu W, Luo G, Huang H, Liu XL

Citation: Huang ZY, Wu W, Luo G, et al. Infection risk associated with talquetamab in relapsed/refractory multiple myeloma: a systematic review with meta-analysis of talquetamab monotherapy and descriptive analysis of combination therapy. Frontiers in immunology. 2026;17:1848518. doi:10.3389/fimmu.2026.1848518

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →